Bleakley Financial Group LLC Buys 25,800 Shares of Pfizer Inc. $PFE

Bleakley Financial Group LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 17.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 173,587 shares of the biopharmaceutical company’s stock after purchasing an additional 25,800 shares during the period. Bleakley Financial Group LLC’s holdings in Pfizer were worth $4,874,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. WJ Financial Advisors LLC boosted its position in shares of Pfizer by 4.3% during the 1st quarter. WJ Financial Advisors LLC now owns 11,123 shares of the biopharmaceutical company’s stock worth $312,000 after purchasing an additional 456 shares in the last quarter. Principal Financial Group Inc. increased its position in Pfizer by 0.5% in the 1st quarter. Principal Financial Group Inc. now owns 6,339,372 shares of the biopharmaceutical company’s stock valued at $178,010,000 after buying an additional 32,564 shares in the last quarter. Citizens National Bank Trust Department increased its position in Pfizer by 3.7% in the 1st quarter. Citizens National Bank Trust Department now owns 48,294 shares of the biopharmaceutical company’s stock valued at $1,356,000 after buying an additional 1,739 shares in the last quarter. Chicago Partners Investment Group LLC raised its stake in Pfizer by 13.4% during the 1st quarter. Chicago Partners Investment Group LLC now owns 93,273 shares of the biopharmaceutical company’s stock worth $2,500,000 after buying an additional 11,016 shares during the period. Finally, Vantage Point Financial LLC boosted its holdings in Pfizer by 2.5% in the first quarter. Vantage Point Financial LLC now owns 21,256 shares of the biopharmaceutical company’s stock worth $597,000 after acquiring an additional 514 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on PFE shares. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. HSBC downgraded shares of Pfizer from a “buy” rating to a “hold” rating and reduced their price target for the company from $32.00 to $28.00 in a research report on Monday, July 6th. CICC Research began coverage on shares of Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target for the company. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. Finally, Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a research note on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $28.50.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst coverage remains supportive, even after some modest price-target cuts. BMO kept an outperform rating and Guggenheim maintained a buy, suggesting Wall Street still sees upside from current levels. Benzinga analyst update
• Positive Sentiment: Pfizer’s oncology franchise is in focus ahead of Q2 results, with growth from key cancer drugs, biosimilars, and pipeline updates potentially helping offset declines in older medicines. Zacks oncology outlook
• Positive Sentiment: Investors are also encouraged by the long-term case for Pfizer’s Seagen integration, which some analysts argue could improve oncology growth and create durable value versus peers like Amgen. 247WallSt Pfizer vs. Amgen
• Neutral Sentiment: Pfizer’s dividend yield remains unusually high at about 7.1%, which may attract income investors, but it also raises questions about whether the payout reflects slower growth expectations. Motley Fool dividend article
• Negative Sentiment: Near-term earnings expectations are soft, with Wall Street looking for a double-digit decline in profit in the next quarterly report, reinforcing concerns about pressure on Pfizer’s core business. Barchart earnings preview
• Negative Sentiment: Drug-pricing headlines tied to the Trump administration are adding policy uncertainty across big pharma, including Pfizer, even though pipeline strength may ultimately matter more. Motley Fool drug-pricing article

Pfizer Stock Performance

Shares of PFE stock opened at $24.24 on Wednesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The firm has a 50-day moving average of $25.28 and a 200-day moving average of $26.18. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The company has a market cap of $138.17 billion, a P/E ratio of 18.51 and a beta of 0.35.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the previous year, the company earned $0.92 earnings per share. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is presently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.